Russia's loss can be India's gain in clinical trial shift, say experts

India's contribution to global clinical trials has been around 4 percent in the last decade while it's the second most populous country in the world, and has one-fifth of the global disease burden

Clinical trials that have halted recruiting participants in Russia and Ukraine owing to geopolitical tensions can be re-allocated to India, say industry insiders.

India’s contribution to global clinical trials has been around 4 per cent in the past decade while being the second-most populous country in the world with one-fifth of the global disease burden.

A recent report by PwC and the US-India Chamber of Commerce, titled “Clinical Trial Opportunities in India”, pointed out that a significant number of phase-3 clinical trials sponsored by big pharma with sites in Russia and Ukraine were still not recruiting participants, and India was